Abstract
Control of cardiovascular (CV) risk factors, particularly hypertension, is still unsatisfactory, resulting in excess CV morbidity and mortality worldwide. CV risk is linearly associated with an increase in blood pressure (BP) values, and clinical studies have clearly demonstrated that BP lowering represents the most effective means of preventing CV events. However, while BP reduction is a fairly easy target, BP normalization is much more difficult to achieve, and adequate BP control (<140/90 mmHg) is attained only in a small percentage of the hypertensive population.
One of the main reasons for the lack of efficacy of antihypertensive pharmacological treatment is that very often drugs are not administered at the correct dosage. In this review, we discuss the importance of using clinical pharmacology to guide treatment of hypertension.
Controlled clinical trials, including HOPE, EUROPA, and CONSENSUS, are used to guide prescribing decisions. Unfortunately, the results obtained in pivotal studies such as these have been obtained using drug dosages much higher than those usually used in clinical practice. The prescription of a drug for the treatment of hypertension should take into consideration the potency of the drug, i.e. the degree of BP reduction required, and the duration of action of the drug, i.e. the need to cover the dosing interval (possibly 24 hours) in a homogeneous way.
This is especially the case for angiotensin-converting enzyme (ACE) inhibitors, compounds characterized by a flat dose-response curve. The significance of this flat dose-response curve is that a low dose of an ACE inhibitor has the same potency as a high dose but a shorter duration of action. If a low dosage is administered to a hypertensive patient it causes BP fluctuations, which have been associated with negative CV outcomes.
In contrast, other drug classes, including calcium channel antagonists, diuretics, and b-adrenoceptor antagonists, can be used at different dosages in order to modulate their hemodynamic effects.
Thus, it is important to be aware of the clinical pharmacology of antihypertensive drugs in order to choose not only the class or the molecule best suited to the clinical characteristics of the patient, but also the correct dosages to ensure effective and homogeneous 24-hour BP reduction.
Similar content being viewed by others
References
Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747–57.
Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–40.
Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347–60.
Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13.
Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35.
Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87.
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121–58.
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–23.
Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22(12): 2387–96.
Ezzati M, Oza S, Danaei G, et al. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117(7): 905–14.
Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20(8): 1461–4.
Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009; 11(3): 190–6.
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403–19.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53.
Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.
Salvetti A, Di Venanzio L, Arrighi P, et al. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors? J Hypertens 1994 Suppl.; 12(8): S91–4; discussion S94–5.
Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5(1): 93–8.
Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11(10): 1133–7.
Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225(2): 101–5.
Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43(1): 4–9.
Elliott HL, Meredith PA, Vincent J, et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986; 21 Suppl. 1: 27S–31S.
Salvetti A, Di Venanzio L. Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S31–4.
Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S–29S.
Smith DH. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs 2007; 7(5): 347–56.
Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008; 29(14): 1739–52.
Drugs.com: drug information online. Enalapril [online]. Available from URL: http://www.drugs.com/pro/enalapril-tablets.html [Accessed 2010 Nov 1].
Drugs.com: drug information online. Ramipril [online]. Available from URL: http://www.drugs.com/pro/ramipril.html [Accessed 2010 Nov 1].
Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18(9): 599–606.
Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group? J Hypertens 1997; 15(12 Pt 1): 1511–8.
Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S52–5.
Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24(1): 3–10.
Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28.
Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987; 5(4): S139–42.
Chatzikyrkou C, Haller H, Menne J. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril? Expert Opin Pharmacother 2009; 10(11): 1833–40.
Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8(1): 45–50.
Acknowledgments
The authors thank Claire Byrne, from inScience Communications (a Wolters Kluwer business), who provided native English language assistance. This assistance was funded by Recordati.
Prof. Taddei has received honoraria for serving on the speakers bureau for: Servier International, Boehringer Ingelheim, Menarini, Recordati International, Sanofi-Aventis, and Pfizer. Dr Ghiadoni has received honoraria for serving on the speakers bureau for Recordati and Servier. Dr Bruno has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taddei, S., Bruno, R.M. & Ghiadoni, L. The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology. Am J Cardiovasc Drugs 11, 13–20 (2011). https://doi.org/10.2165/11586670-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586670-000000000-00000